\
&
Contact us
\
&
Contact us
Starts in 1 week from now
LocationOnline
ProgrammesThis MSCA lunchtime conversation focuses on the potential of human-AI interaction and collaboration. It will explore how to optimally integrate the strengths of humans and machines in the future. This is essential to optimise the efficiency and robustness of such collaborative work, increase the uptake and acceptance of AI across sectors and user groups by ensuring that AI systems are human-centered.
Speakers will present the knowledge and tools developed in EU-funded projects, which will serve as a basis for the discussion and exchange among the panelists and with the audience.
Deadline to register: 21 May 2025, 12.00 CEST
More information and the registration link is available in the announcement on the MSCA website.
Programme in brief
12:30 - 12:45 Event introduction, policy context and project data by MSCA
12:45 - 13:45 Discussion panel: Human AI co-creation with representatives from a MSCA Innovative Training Network and ERC Consolidator grant
13:45 - 13:55 Policy reflections
13:55 - 14:00 Wrap up and announcement of next events
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
